UPMC Enterprises, the medical technology investment arm of UPMC, has purchased interest in RxAnte, a company that uses analytics to predict how patients will adhere to the medications they’re prescribed.
Read more on Pittsburgh Business Times.
Pittsburgh Business Times: UPMC Enterprises invests in prescription analytics company RxAnte
Related Resources
More Resources
07.29.19
Introducing RxAnte’s Solution for Better Medication Use
Blog Post
When it comes to medication use, the ability to provide health plans with effective resources for monitoring and intervention is key to reducing costs and improving care quality ratings. RxAnte's latest enhancement provides a solution to address new prescription recommendation measures, on top of the existing triple-weighted adherence measures for 2020 CMS Star Ratings.
06.25.19
Artificial Intelligence and Effective Adherence Programs
Blog Post
At RxAnte, we are often asked whether we use artificial intelligence (AI) as part of our adherence solution. The short answer to this question is ‘yes,’ but there is more nuance to this tool we find timely to explore. Here, we go beyond buzzwords like AI and into the significance of machine learning as part of a successful medication adherence solution.
06.12.19
RxEffect Functionality Reflects the Dynamic Nature of Quality Improvement
Blog Post
RxAnte is proud to present “All Quality Improvement Patients” in our patented RxEffect tool. This update enables seamless care coordination by tracking patients over the current calendar year. RxEffect can now be the sole population management tool for medication-related quality improvement initiatives.